Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964560 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT01964560 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 540 participants.
The verdict
NCT01964560, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of lacosamide (LCM) in pediatric subjects.
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964560
The ClinicalTrials.gov registry entry for NCT01964560 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT01964560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964560 about?
NCT01964560 is a clinical study titled "A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures". The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of lacosamide (LCM) in pediatric subjects.
What is the current status of trial NCT01964560?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2014-08-13. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT01964560?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01964560?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.